Optimal Remifentanil Concentration and Thyroidectomy (ORCO)

University of Cagliari

Status: Unknown

Conditions: Anesthesia

Treatments: Other: Remifentanil Effect site concentration

Study type: Interventional

Funder types: Other

Identifiers

NCT03218124

Remismooth2217

Details and patient eligibility

About

The study is aimed at determining the remifentanil effect site concentration suppressing the cough at extubation after surgical thyroidectomy, performed under remifentanil/desflurane based general anesthesia, expressed as median and 95th percentile effective dose.

Possible hemodynamic instability, respiratory depression or prolongation of awakening time are also sought.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 67 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18<age<67
• 6 hrs fasting
• American society of anesthesiology (ASA) Physical Status I o II
• Informed consent

Exclusion criteria

• Absence of inclusion criteria
• Use of cough suppressors, angiotensin converting enzyme-inhibitors, sedatives 4 weeks before surgery
• Arhythmia, pacemaker or unstable cardiovascular disease
• Hepatic or renal failure
• Anticipated difficulty in airways management
• Chronic obstructive pulmonary disease (COPD), Asthma, increased risk for inhalation, airway infection in the previous 4 weeks;
• Smoker
• Obesity (BMI >35)
• Pregnancy
• Hypersensitivity to drugs administered for the study

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

remifentanil

Experimental group

Description:

After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise ("Dixon's up and down" method).

Treatment:

Other: Remifentanil Effect site concentration